Recio-Rodriguez José I, Gómez-Marcos Manuel A, Agudo-Conde Cristina, Ramirez Ignasi, Gonzalez-Viejo Natividad, Gomez-Arranz Amparo, Salcedo-Aguilar Fernando, Rodriguez-Sanchez Emiliano, Alonso-Domínguez Rosario, Sánchez-Aguadero Natalia, Gonzalez-Sanchez Jesus, Garcia-Ortiz Luis
Primary Health Care Research Unit, La Alamedilla Health Center, Health Service of Castilla y León (SACYL), Biomedical Research Institute of Salamanca (IBSAL), Spanish Network for Preventive Activities and Health Promotion (REDIAPP) Department of Nursing and Physiotherapy Department of Medicine, University of Salamanca Centro de Salud Sta Ponça de Palma de Mallorca, Spanish Network for Preventive Activities and Health Promotion (REDIAPP) Torre Ramona Health Center, Aragon Health Service, Zaragoza Casa del Barco Health Center, Castilla y León Health Service, Valladolid Cuenca III Health Center, Castilla la Mancha Health Service (SESCAM) Department of Nursing, University of Extremadura Department of Biomedical and Diagnostic Sciences, University of Salamanca,Spain.
Medicine (Baltimore). 2018 Jan;97(2):e9633. doi: 10.1097/MD.0000000000009633.
Mobile technology, when included within multicomponent interventions, could contribute to more effective weight loss. The objective of this project is to assess the impact of adding the use of the EVIDENT 3 application, designed to promote healthy living habits, to traditional modification strategies employed for weight loss. Other targeted behaviors (walking, caloric-intake, sitting time) and outcomes (quality of life, inflammatory markers, measurements of arterial aging) will also be evaluated.
Randomized, multicentre clinical trial with 2 parallel groups. The study will be conducted in the primary care setting and will include 700 subjects 20 to 65 years, with a body mass index (27.5-40 kg/m), who are clinically classified as sedentary. The primary outcome will be weight loss. Secondary outcomes will include change in walking (steps/d), sitting time (min/wk), caloric intake (kcal/d), quality of life, arterial aging (augmentation index), and pro-inflammatory marker levels. Outcomes will be measured at baseline, after 3 months, and after 1 year. Participants will be randomly assigned to either the intervention group (IG) or the control group (CG). Both groups will receive the traditional primary care lifestyle counseling prior to randomization. The subjects in the IG will be lent a smartphone and a smartband for a 3-month period, corresponding to the length of the intervention. The EVIDENT 3 application integrates the information collected by the smartband on physical activity and the self-reported information by participants on daily food intake. Using this information, the application generates recommendations and personalized goals for weight loss.
There is a great diversity in the applications used obtaining different results on lifestyle improvement and weight loss. The populations studied are not homogeneous and generate different results. The results of this study will help our understanding of the efficacy of new technologies, combined with traditional counseling, towards reducing obesity and enabling healthier lifestyles.
The study was approved by the Clinical Research Ethics Committee of the Health Area of Salamanca ("CREC of Health Area of Salamanca") on April 2016. A SPIRIT checklist is available for this protocol. The trial was registered in ClinicalTrials.gov provided by the US National Library of Medicine-number NCT03175614.
移动技术若包含在多成分干预措施中,可能有助于更有效地减肥。本项目的目的是评估在传统的减肥策略中增加使用旨在促进健康生活习惯的EVIDENT 3应用程序的影响。还将评估其他目标行为(步行、热量摄入、久坐时间)和结果(生活质量、炎症标志物、动脉老化测量)。
采用随机、多中心临床试验,分为2个平行组。该研究将在初级保健机构进行,纳入700名年龄在20至65岁之间、体重指数为27.5至40kg/m²且临床分类为久坐不动的受试者。主要结局将是体重减轻。次要结局将包括步行变化(步数/天)、久坐时间(分钟/周)、热量摄入(千卡/天)、生活质量、动脉老化(增强指数)和促炎标志物水平。结局将在基线、3个月后和1年后进行测量。参与者将被随机分配到干预组(IG)或对照组(CG)。两组在随机分组前均将接受传统的初级保健生活方式咨询。干预组的受试者将被借给一部智能手机和一个智能手环,为期3个月,与干预时长一致。EVIDENT 3应用程序整合了智能手环收集的身体活动信息以及参与者自行报告的每日食物摄入量信息。利用这些信息,该应用程序生成减肥建议和个性化目标。
在用于改善生活方式和减肥的应用程序方面存在很大差异,所获得的结果也各不相同。所研究的人群并不同质,产生的结果也不同。本研究的结果将有助于我们理解新技术与传统咨询相结合对减少肥胖和实现更健康生活方式的疗效。
该研究于2016年4月获得萨拉曼卡健康区临床研究伦理委员会(“萨拉曼卡健康区CREC”)的批准。本方案有一份SPIRIT检查表。该试验已在美国国立医学图书馆提供的ClinicalTrials.gov上注册,编号为NCT03175614。